Dougall, William C <br/><br/>
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.  [electronic resource] 

 -  Immunological reviews  03 2017 
 - 112-120 p.  digital 
<br/><br/> Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1600-065X 
<br/><br/><label>Standard No.: </label>10.1111/imr.12518  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--therapeutic use<br/>Antigens, CD--immunology<br/>Antigens, Differentiation, T-Lymphocyte--metabolism<br/>CTLA-4 Antigen--immunology<br/>Humans<br/>Immunotherapy--methods<br/>Killer Cells, Natural--immunology<br/>Lymphocyte Activation<br/>Neoplasms--immunology<br/>Programmed Cell Death 1 Receptor--immunology<br/>Receptors, Immunologic--immunology<br/>Signal Transduction<br/>T-Lymphocytes--immunology<br/>Tumor Escape<br/>T Lineage-Specific Activation Antigen 1